Genetic variations in heme oxygenase-1 and chronic hepatitis

Hepatology

Volumn 52, Issue 1, 2010, Pages 400-401

  Bonkovsky, Herbert L ^a   Lambrecht, Richard W ^b   Naishadham, Deepa ^c  

^a CAROLINAS MEDICAL CENTER   (United States)

^b UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^c NEW ENGLAND RESEARCH INSTITUTES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BILIVERDIN; CARBON MONOXIDE; HEME OXYGENASE 1; INTERFERON; IRON; RIBAVIRIN;

AFRICAN AMERICAN; ANTIVIRAL THERAPY; ARTHRITIS; CAUCASIAN; CELL PROTECTION; CHRONIC HEPATITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CORONARY ARTERY DISEASE; DIABETES MELLITUS; ENZYME DEGRADATION; GENE EXPRESSION; GENETIC ANALYSIS; GENETIC VARIABILITY; HEPATITIS C; HYPOTHESIS; LETTER; OXIDATIVE STRESS; PRIORITY JOURNAL; PROMOTER REGION; REPLICON; RISK ASSESSMENT; SHORT TANDEM REPEAT; TREATMENT RESPONSE; UPREGULATION; VIRUS GENE;

ANTIVIRAL AGENTS; CONTINENTAL POPULATION GROUPS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENETIC VARIATION; HEME OXYGENASE-1; HEPATITIS C, CHRONIC; HUMANS; PROGNOSIS; PROMOTER REGIONS, GENETIC; TREATMENT OUTCOME; UNITED STATES;

EID: 77954232904     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.23562     Document Type: Letter

References (9)

1. Lehmann E, El-Tantawy WH, Ocker M, Bartenschlager R, Lohmann V, Hashemolhosseini S, et al. The heme oxygenase 1 product biliverdin interferes with hepatitis C virus replication by increasing antiviral interferon response. HEPATOLOGY 2010;51:398-404.
2. Bonkovsky HL, Elbirt KK. Heme oxygenase: its regulation and role. (Chapter 41) In: Cutler RG, Rodriguez H, eds. Oxidative Stress and Aging: Advances in Basic Science, Diagnostics, and Intervention. River Edge, NJ: World Scientific Publishing; 2002:699-706.
3. Abraham NG, Kappas A. Pharmacological and clinical aspects of heme oxygenase. Pharmacol Rev 2008;60:79-127. (Pubitemid 351439218)
4. Abdalla MY, Britigan BE, Wen F, Icardi M, McCormick ML, LaBrecque DR, et al. Down-regulation of heme oxygenase-1 by hepatitis C virus infection in vivo and the in vitro expression of hepatitis C core protein. J Infect Dis 2004;190:1109-1118. (Pubitemid 39186798)
5. Muriel P. Role of free radicals in liver diseases. Hepatol Int. 2009 Nov 26. PMID 19941170 [epub ahead of print].
6. Di Bisceglie AM, Shiffman ML, Everson GT, Lindsay KL, Everhart JE, Wright EC, et al. Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. N Engl J Med 2008;359: 2429-2441.
7. Lee WM, Dienstag JL, Lindsay KL, Lok AS, Bonkovsky HL, Shiffman ML, et al. Evolution of the HALT-C Trial: pegylated interferon as maintenance therapy for chronic hepatitis C in previous interferon nonresponders. Control Clin Trials 2004;25:472-492.
8. Lüblinghoff N, Winkler K, Winkelmann BR, Seelhorst U, Wellnitz B, Boehm BO, et al. Genetic variants of the promoter of the heme oxygenase-1 gene and their influence on cardiovascular disease (the Ludwigshafen Risk and Cardiovascular Health Study). BMC Med Genet 2009;10:36.
9. Exner M, Minar E, Wagner O, Schillinger M. The role of heme oxygenase-1 promoter polymorphisms in human disease. Free Radic Biol Med 2004;37:1097-1104. (Pubitemid 39296737)